Applied DNA Sciences Files 8-K
Ticker: BNBX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 744452
Sentiment: neutral
Topics: 8-K, financial-statements, exhibits
Related Tickers: APDN
TL;DR
APDN filed an 8-K on Oct 23, 2025, reporting events as of Oct 21, 2025. Mostly financial statements and exhibits.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on October 23, 2025, reporting events as of October 21, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates routine corporate reporting, likely containing updated financial information or exhibit filings that are standard for public companies.
Risk Assessment
Risk Level: low — The filing appears to be routine and does not disclose any immediate material changes or negative news.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- October 21, 2025 (date) — Earliest event reported
- October 23, 2025 (date) — Filing date
- 50 Health Sciences Drive (address) — Company address
- Stony Brook, New York 11790 (address) — Company location
FAQ
What is the primary purpose of this 8-K filing?
The filing is a Current Report on Form 8-K, primarily reporting 'Other Events' and 'Financial Statements and Exhibits' as of October 21, 2025.
When was this 8-K filed with the SEC?
The filing was made on October 23, 2025.
What is the earliest event date reported in this filing?
The earliest event reported is dated October 21, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 50 Health Sciences Drive, Stony Brook, New York 11790.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.
Filing Stats: 667 words · 3 min read · ~2 pages · Grade level 9.8 · Accepted 2025-10-22 21:06:35
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BNBX The Nasdaq Stock Mar
- $3.32 — ited investors, at an offering price of $3.32 per share, an aggregate of 4,620,485 sh
- $0.0001 — ed warrants having an exercise price of $0.0001 per share), and Series E-1 Warrants to
- $3.82 — Stock at a per share exercise price of $3.82 (such offering, the "Cash Offering"); a
- $15.3 million — oss proceeds from the Offering included $15.3 million in cash and stablecoins and units of th
- $11.71 million — s and units of the OBNB trust valued at $11.71 million (as of October 22, 2025). The Company r
Filing Documents
- tm2529307d1_8k.htm (8-K) — 24KB
- tm2529307d1_ex99-1.htm (EX-99.1) — 22KB
- tm2529307d1_ex99-1img03.jpg (GRAPHIC) — 24KB
- tm2529307d1_ex99-1img04.jpg (GRAPHIC) — 23KB
- 0001104659-25-101630.txt ( ) — 277KB
- bnbx-20251021.xsd (EX-101.SCH) — 3KB
- bnbx-20251021_lab.xml (EX-101.LAB) — 33KB
- bnbx-20251021_pre.xml (EX-101.PRE) — 22KB
- tm2529307d1_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On October 22, 2025, Applied DNA Sciences, Inc. (the "Company") announced the closing of its previously announced private placement offerings in which, (i) the Company sold to certain accredited investors, at an offering price of $3.32 per share, an aggregate of 4,620,485 shares of common stock of the Company, par value $0.001 per share (the "Common Stock"), and/or prefunded warrants in lieu thereof (with such prefunded warrants having an exercise price of $0.0001 per share), and Series E-1 Warrants to purchase 4,620,485 shares of Common Stock at a per share exercise price of $3.82 (such offering, the "Cash Offering"); and (ii) the Company sold to certain accredited investors, at an offering price of $3.32 per share, 3,444,191 prefunded warrants to purchase shares of Common Stock (with such prefunded warrants having an exercise price of $0.0001 per share) and 3,444,191 Series E-2 Warrants at a per share exercise of $3.82 (such offering, the "Cryptocurrency Offering," and together with the Cash Offering, the "Offering"). Gross proceeds from the Offering included $15.3 million in cash and stablecoins and units of the OBNB trust valued at $11.71 million (as of October 22, 2025). The Company received 0.126 units of OBNB trust per prefunded warrant and common warrant for a total of 435,638 trust units representing underlying ownership of 10,647 BNB tokens. The Company previously disclosed the Offering in Current Reports on Form 8-K filed with the Securities and Exchange Commission on September 29, 2025 and on October 1, 2025. On October 22, 2025, the Company issued a press release announcing the closing and gross proceeds of the Offering. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated October 22, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: October 22, 2025 APPLIED DNA SCIENCES, INC. By: /s/ Beth Jantzen Name: Beth Jantzen Title: Chief Financial Officer